Along with the investment, Bayer will also work with Medopad to build AI-driven digital therapies specifically to track heart health. The startup has ongoing projects with Johnson & Johnson’s Janssen Pharmaceuticals to develop a digital biomarker for Alzheimer’s disease; it previously partnered with Apple to develop a medication management and adherence Apple Watch app for chemotherapy patients.
Medopad is also a member of the Discover-NOW initiative, alongside Google Health, AstraZeneca and IBM, to create the Health Data Research Hub for Real-World Evidence.
More articles on health IT:
Malcolm Gladwell: 3 reasons for the ‘lag’ between innovation and adoption
Lasers can hack Amazon Alexa, other smart speakers from afar, study finds
DNA-testing company informs consumers of data breach
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
